2616 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2616 from our risk checks.
CStone Pharmaceuticals Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.40 |
52 Week High | HK$2.95 |
52 Week Low | HK$0.80 |
Beta | 0.23 |
11 Month Change | 12.00% |
3 Month Change | 22.81% |
1 Year Change | -35.48% |
33 Year Change | -88.78% |
5 Year Change | -88.89% |
Change since IPO | -89.11% |
Recent News & Updates
Recent updates
Improved Revenues Required Before CStone Pharmaceuticals (HKG:2616) Stock's 27% Jump Looks Justified
May 12Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long
Apr 29Shareholder Returns
2616 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -11.4% | -0.4% | -3.5% |
1Y | -35.5% | -22.0% | -1.0% |
Return vs Industry: 2616 underperformed the Hong Kong Biotechs industry which returned -22% over the past year.
Return vs Market: 2616 underperformed the Hong Kong Market which returned -1% over the past year.
Price Volatility
2616 volatility | |
---|---|
2616 Average Weekly Movement | 5.9% |
Biotechs Industry Average Movement | 6.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.2% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 2616 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2616's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 230 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
2616 fundamental statistics | |
---|---|
Market cap | HK$1.91b |
Earnings (TTM) | -HK$402.60m |
Revenue (TTM) | HK$508.51m |
3.5x
P/S Ratio-4.4x
P/E RatioIs 2616 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2616 income statement (TTM) | |
---|---|
Revenue | CN¥463.84m |
Cost of Revenue | CN¥159.55m |
Gross Profit | CN¥304.30m |
Other Expenses | CN¥671.53m |
Earnings | -CN¥367.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.29 |
Gross Margin | 65.60% |
Net Profit Margin | -79.17% |
Debt/Equity Ratio | 69.8% |
How did 2616 perform over the long term?
See historical performance and comparison